Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410854 | 0.93 | CNR2 (0.44) | CNR2KMT2ASMN1; SMN2CNR1 | |
| SCHEMBL5456447 | 0.91 | CNR2 (0.49) | CNR2KMT2ACNR1HTR2AGRM2 | |
| SCHEMBL5446783 | 0.91 | HRH2 (0.42) | CNR2KMT2ACNR1HTR2A | |
| SCHEMBL5455254 | 0.90 | PRPS1 (0.43) | CNR2CNR1HTR2A | |
| SCHEMBL14411850 | 0.90 | PRPS1 (0.43) | CNR2CNR1HTR2A | |
| SCHEMBL5453439 | 0.90 | CNR2 (0.49) | CNR2KMT2ACNR1 | |
| SCHEMBL14464386 | 0.89 | CNR2 (0.39) | CNR2HTR2A | |
| SCHEMBL5460386 | 0.87 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL5441919 | 0.86 | KMT2A (0.43) | CNR2KMT2ASMN1; SMN2CNR1HTR2A | |
| SCHEMBL14410851 | 0.86 | CNR2 (0.46) | CNR2KMT2ASMN1; SMN2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885KMT2A 4056/4885SMN1; SMN2 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.